Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer

Piao, Yong-Rui; Li, Piao; Zhu, Lianhua; Jin, Zhehu; Dong, Xiaorong

doi:10.7314/apjcp.2013.14.6.3897

Cited by 49 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tim-3 has previously been reported to be expressed at high levels in prostate cancer, hepatocellular carcinoma, renal cell carcinoma and melanoma (18–20,22,23). In line with these reports, the present study found that the expression of Tim-3 was significantly higher in CRC cancerous samples, compared with adjacent non-cancerous samples.…”

Section: Discussionmentioning

confidence: 99%

“…Of note, with the exception of the immune response, increasing evidence has suggested that Tim-3 has functional roles in tumor biology. The expression of Tim-3 in peripheral blood monocytes and in tumor tissues has been suggested to be prognostic in prostate cancer (18). Tim-3 may affect development and progression, and be a therapeutic target in prostate cancer (19).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Lü

Liu

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

T cell immunoglobulin mucin-3 (Tim-3) has previously been implicated in the immune response and tumor biology. Colorectal carcinoma (CRC) is a malignancy, which is closely associated with inflammation. However, the role of Tim-3 in the progression of CRC remains to be fully elucidated. The present study aimed to investigate the role of Tim-3 in the progressive activities of human CRC. A total of 30 clinical CRC tissues and their adjacent tissues were collected. Slides from another 112 cases that underwent CRC surgical resection were also obtained. The protein and mRNA levels of Tim-3 in the clinical tissues and in CRC cell lines were initially examined using western blot and reverse transcription-quantitative polymerase chain reaction analyses, respectively. Immunohistochemical staining was performed to detect Tim-3 in the CRC samples. Specific small interfering (si)RNA against Tim-3 (siTim-3) was synthesized to knock down the expression of Tim-3, and the subsequent effects of Tim-3 knockdown on cell proliferation, migration and invasion were assessed. The data obtained showed that Tim-3 was expressed at high levels in the CRC tissues, compared with the non-cancerous tissues. The expression of Tim-3 in the clinical tissues was significantly associated with tumor size (P=0.007), tumor-node-metastasis staging (P<0.0001) and distant metastasis (P<0.0001). Knockdown of Tim-3 significantly reduced the cell proliferative rate of HCT116 and HT-29 cells. Wound closure activity was also inhibited by knockdown of Tim-3 in these two cell lines, and the migration and invasive abilities of these two cell lines were consistently decreased following knockdown of Tim-3. Taken together, Tim-3 was found to be a critical mediator in the progression of CRC and may serve as a potential therapeutic target for the treatment of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Lü

Liu

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…38 The ectopic expression of TIM-3 in tumor cells has been suggested as a potential, independent prognostic factor for patients with lung cancer, 36 cervical cancer 37 and prostate cancer. 39 The Tim-3/galectin-9 signaling pathway mediates Tcell senescence was also involved in patients with hepatitis B virus (HBV)-associated HCC, thus it has been a potential immunotherapeutic target. 40 In addition, polymorphisms in TIM-3 gene were showed to be associated with various cancers.…”

Section: Introductionmentioning

confidence: 99%

Tim-3 and Tim-4 as the potential targets for antitumor therapy

Cheng

Ruan

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Combined in vitro blockade with both TIM-3 and PD-1 was able to restore effector cytokine secretion. A recent study of benign and cancerous tissue from 137 treatment-naïve prostate cancer patients found weak TIM-3 expression in benign tissue compared to up-regulation in both PIN and invasive carcinomas[88]. Univariate analysis showed a significant association with TNM stage, nuclear grade and recurrence-free or progression-free survival.…”

Section: Iv: Other Checkpoint Molecules – Lag-3 Tim-3b7-h3 and B7-hmentioning

confidence: 99%

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview

Alme

Karir

Faltas

et al. 2016

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell-surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking one of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies. The objective responses seen in these early trials of checkpoint blockade are driving renewed enthusiasm for cancer immunotherapy. There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade.

show abstract

Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer

Cited by 49 publications

References 16 publications

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Tim-3 and Tim-4 as the potential targets for antitumor therapy

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview

Contact Info

Product

Resources

About